MA33430B1 - Dérivés de pyrazinooxazépine - Google Patents

Dérivés de pyrazinooxazépine

Info

Publication number
MA33430B1
MA33430B1 MA34535A MA34535A MA33430B1 MA 33430 B1 MA33430 B1 MA 33430B1 MA 34535 A MA34535 A MA 34535A MA 34535 A MA34535 A MA 34535A MA 33430 B1 MA33430 B1 MA 33430B1
Authority
MA
Morocco
Prior art keywords
pyrazinoxazepine
derivatives
compound
serotonin
obesity
Prior art date
Application number
MA34535A
Other languages
Arabic (ar)
English (en)
Inventor
Shigekazu Sasaki
Tomokazu Kusumoto
Izumi Nomura
Hironobu Maezaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA33430B1 publication Critical patent/MA33430B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION PORTE SUR UN COMPOSÉ AYANT UNE ACTION ACTIVANT LE RÉCEPTEUR 5-HT2C DE LA SÉROTONINE, UTILE POUR DES ÉTATS CONCERNANT LE TRACTUS URINAIRE INFÉRIEUR, L'OBÉSITÉ ET LE CANCER. L'INVENTION PORTE SUR UN COMPOSÉ REPRÉSENTÉ PAR LA FORMULE (IO) : DANS LAQUELLE CHAQUE SYMBOLE EST TEL QUE DÉFINI DANS LA DESCRIPTION, OU UN SEL DE CELUI-CI.
MA34535A 2009-06-15 2010-06-14 Dérivés de pyrazinooxazépine MA33430B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009142673 2009-06-15
PCT/JP2010/060408 WO2010147226A1 (fr) 2009-06-15 2010-06-14 Dérivés de pyrazinooxazépine

Publications (1)

Publication Number Publication Date
MA33430B1 true MA33430B1 (fr) 2012-07-03

Family

ID=42561089

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34535A MA33430B1 (fr) 2009-06-15 2010-06-14 Dérivés de pyrazinooxazépine

Country Status (40)

Country Link
US (4) US9115139B2 (fr)
EP (1) EP2442870B1 (fr)
JP (2) JP5579262B2 (fr)
KR (1) KR101768234B1 (fr)
CN (1) CN102458579B (fr)
AR (1) AR077094A1 (fr)
AU (1) AU2010260847B2 (fr)
BR (1) BRPI1011502A2 (fr)
CA (1) CA2765239C (fr)
CL (1) CL2011003154A1 (fr)
CO (1) CO6491037A2 (fr)
CR (1) CR20120021A (fr)
CY (1) CY1115483T1 (fr)
DK (1) DK2442870T3 (fr)
DO (1) DOP2011000393A (fr)
EA (1) EA021079B1 (fr)
EC (1) ECSP12011603A (fr)
ES (1) ES2480275T3 (fr)
GE (1) GEP20146168B (fr)
HR (1) HRP20140589T1 (fr)
IL (1) IL216761A (fr)
JO (1) JO3087B1 (fr)
MA (1) MA33430B1 (fr)
ME (1) ME01835B (fr)
MX (1) MX2011013081A (fr)
MY (1) MY157497A (fr)
NZ (1) NZ597507A (fr)
PE (1) PE20121049A1 (fr)
PL (1) PL2442870T3 (fr)
PT (1) PT2442870E (fr)
RS (1) RS53414B (fr)
SG (1) SG176696A1 (fr)
SI (1) SI2442870T1 (fr)
SM (1) SMT201400080B (fr)
TN (1) TN2011000630A1 (fr)
TW (2) TW201529584A (fr)
UA (1) UA108357C2 (fr)
UY (1) UY32707A (fr)
WO (1) WO2010147226A1 (fr)
ZA (1) ZA201109370B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2727585A1 (fr) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited Méthode de dépistage in-vivo
JP5579262B2 (ja) * 2009-06-15 2014-08-27 武田薬品工業株式会社 ピラジノオキサゼピン誘導体
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
JP2014201578A (ja) * 2013-04-09 2014-10-27 武田薬品工業株式会社 線維筋痛症治療剤
JP2014214132A (ja) * 2013-04-26 2014-11-17 武田薬品工業株式会社 ニコチン依存症の予防・治療剤
WO2015066344A1 (fr) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation
WO2017026538A1 (fr) 2015-08-07 2017-02-16 Takeda Pharmaceutical Company Limited Procédé de production de pyrazine
WO2017111178A1 (fr) 2015-12-24 2017-06-29 Takeda Pharmaceutical Company Limited Préparation solide
US9985579B2 (en) 2016-04-12 2018-05-29 Preformed Line Products Co. Mounting assembly for mounting a solar panel
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
CA2428905A1 (fr) 2000-11-20 2002-05-23 Biovitrum Ab Composes de piperazinylpyrazines utilises comme antagonistesdu recepteur de la serotonine 5-ht2
WO2002083863A2 (fr) 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole et autres ligands heterocycliques pour recepteurs et transporteurs mammaliens de serotonine, de dopamine et de la muscarine, et methodes d'utilisation correspondantes
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
ES2307102T3 (es) 2002-06-19 2008-11-16 Biovitrum Ab (Publ) Piperazinilpirazinas como moduladores del receptor de la serotonina 5-ht2c.
AU2003243089B2 (en) 2002-06-19 2010-01-07 Biovitrum Ab (Publ) Novel compounds, their use and preparation
CA2514547A1 (fr) 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited Agonistes de recepteurs
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US7704993B2 (en) 2003-06-17 2010-04-27 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
MXPA05013364A (es) 2003-06-17 2006-03-17 Arena Pharm Inc Procedimiento para preparar 3-benzazepinas.
JP2006056881A (ja) 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
JP5237810B2 (ja) 2005-09-01 2013-07-17 イーライ リリー アンド カンパニー ５−ＨＴ２Ｃ受容体アゴニストとしての６−置換された２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン
FR2895259B1 (fr) 2005-12-22 2008-02-22 Urosphere Sas Methodes de traitement des incontinences urinaires
EP2727585A1 (fr) * 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited Méthode de dépistage in-vivo
US8247403B2 (en) 2007-03-07 2012-08-21 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
US20090062253A1 (en) 2007-08-31 2009-03-05 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
EP2216023A4 (fr) 2007-11-15 2013-03-13 Takeda Pharmaceutical Dérivé de pyridine condensé et son utilisation
WO2009063993A1 (fr) * 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited Dérivé de pyridine fusionné et son utilisation
EP2213675B1 (fr) * 2007-11-15 2013-08-14 Takeda Pharmaceutical Company Limited Dérivé de pyridooxazépine et son utilisation
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP5579262B2 (ja) * 2009-06-15 2014-08-27 武田薬品工業株式会社 ピラジノオキサゼピン誘導体

Also Published As

Publication number Publication date
AR077094A1 (es) 2011-08-03
TWI542592B (zh) 2016-07-21
JP2012530051A (ja) 2012-11-29
PT2442870E (pt) 2014-07-16
UA108357C2 (xx) 2015-04-27
MY157497A (en) 2016-06-15
US20100317651A1 (en) 2010-12-16
JO3087B1 (ar) 2017-03-15
NZ597507A (en) 2013-09-27
CO6491037A2 (es) 2012-07-31
TW201529584A (zh) 2015-08-01
EP2442870B1 (fr) 2014-04-16
US20120135979A1 (en) 2012-05-31
TW201109338A (en) 2011-03-16
US8324201B2 (en) 2012-12-04
AU2010260847A1 (en) 2012-01-19
US9115139B2 (en) 2015-08-25
CN102458579A (zh) 2012-05-16
IL216761A (en) 2016-03-31
JP5579203B2 (ja) 2014-08-27
CN102458579B (zh) 2014-11-05
US8314088B2 (en) 2012-11-20
WO2010147226A1 (fr) 2010-12-23
CA2765239C (fr) 2018-08-07
DK2442870T3 (da) 2014-06-30
CR20120021A (es) 2012-03-06
ES2480275T3 (es) 2014-07-25
BRPI1011502A2 (pt) 2016-03-22
MX2011013081A (es) 2012-01-20
EA201270017A1 (ru) 2012-07-30
HK1169623A1 (en) 2013-02-01
US20110288291A1 (en) 2011-11-24
EA021079B1 (ru) 2015-03-31
ME01835B (me) 2014-12-20
SG176696A1 (en) 2012-01-30
CL2011003154A1 (es) 2012-06-15
CY1115483T1 (el) 2017-01-04
ZA201109370B (en) 2012-10-31
GEP20146168B (en) 2014-09-25
TN2011000630A1 (en) 2013-05-24
KR101768234B1 (ko) 2017-08-14
US20110282054A1 (en) 2011-11-17
US8318722B2 (en) 2012-11-27
SMT201400080B (it) 2014-09-08
DOP2011000393A (es) 2012-02-15
RS53414B (sr) 2014-12-31
ECSP12011603A (es) 2012-03-30
IL216761A0 (en) 2012-02-29
CA2765239A1 (fr) 2010-12-23
HRP20140589T1 (hr) 2014-08-01
PL2442870T3 (pl) 2014-12-31
SI2442870T1 (sl) 2014-07-31
JP2012107032A (ja) 2012-06-07
AU2010260847B2 (en) 2016-11-24
JP5579262B2 (ja) 2014-08-27
KR20120034734A (ko) 2012-04-12
UY32707A (es) 2011-01-31
PE20121049A1 (es) 2012-08-22
EP2442870A1 (fr) 2012-04-25

Similar Documents

Publication Publication Date Title
MA32171B1 (fr) Compose heterocyclique
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA33363B1 (fr) Antagonistes de la voie de signalisation hedgehog a base de phtalazine disubstituee
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
UA108357C2 (xx) Похідні піразинооксазепіну
MA30528B1 (fr) Antagoniste du recepteur il-8.
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA32231B1 (fr) Composés organiques
UA97257C2 (en) Indole derivatives
MA34713B1 (fr) Compose bicyclique
EA201270169A1 (ru) Агонисты gpr119
TW200738688A (en) Compounds for the treatment of inflammatory disorders
EA201000113A1 (ru) Пиразольные соединения
MA33032B1 (fr) Pyrimidines condensees
MA33212B1 (fr) Procedes d'amelioration de pharmacocinetique
JP2011510079A5 (fr)
EA200970098A1 (ru) Понизитель водоотдачи для буровых растворов на масляной основе
MA33569B1 (fr) Ligands sigma pour la prevention ou le traitement de la douleur induite par la chimiotherapie
MA32985B1 (fr) Nouveaux microbiocides
BRPI0813870A2 (pt) Síntese catalisada por metal de transição de 2h-indazóis.
EP2173364A4 (fr) Traitement ou prévention d'une infection par un rotavirus
MA34982B1 (fr) Synthese de derives de 2-carboxamidocycloaminouree
MA32997B1 (fr) Macrolide anti-inflammatoire
MA30341B1 (fr) Dérivés de benzimidazole
JO2999B1 (ar) مركب ثلاثي حلقي و استخدامه الدوائي